Structure Therapeutics Inc.

Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline…